Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults

Daniel E. Polsky, Machaon Bonafede, Jose A. Suaya

Research output: Contribution to journalArticle

Abstract

Abstract. Background: Adults with certain comorbid conditions have a higher risk of pneumonia than the overall population. If treatment of pneumonia is more costly in certain predictable situations, this would affect the value proposition of populations for pneumonia prevention. We estimate the economic impact of community-acquired pneumonia (CAP) for adults with asthma, diabetes, chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) in a large U.S. commercially-insured working age population. Methods. Data sources consisted of 2003 through 2007 Thomson Reuters MarketScan Commercial Claims and Encounters and Thomson Reuters Health Productivity and Management (HPM) databases. Pneumonia episodes and selected comorbidities were identified by ICD-9-CM diagnosis codes. By propensity score matching, controls were identified for pneumonia patients. Excess direct medical costs and excess productivity cost were estimated by generalized linear models (GLM). Results: We identified 402,831 patients with CAP between 2003 through 2007, with 25,560, 32,677, 16,343, and 5,062 episodes occurring in patients with asthma, diabetes, COPD and CHF, respectively. Mean excess costs (and standard error, SE) of CAP were $14,429 (SE=44) overall. Mean excess costs by comorbidity subgroup were lowest for asthma ($13,307 (SE=123)), followed by diabetes ($21,395 (SE=171)) and COPD ($23,493 (SE=197)); mean excess costs were highest for patients with CHF ($34,436 (SE=549)). On average, indirect costs comprised 21% of total excess costs, ranging from 8% for CHF patients to 27% for COPD patients. Conclusions: Compared to patients without asthma, diabetes, COPD, or CHF, the excess cost of CAP is nearly twice as high for patients with diabetes and COPD and nearly three times as high for patients with CHF. Indirect costs made up a significant but varying portion of excess CAP costs. Returns on prevention of pneumonia would therefore be higher in adults with these comorbidities.

Original languageEnglish (US)
Article number379
JournalBMC health services research
Volume12
Issue number1
DOIs
StatePublished - Nov 7 2012
Externally publishedYes

Fingerprint

Comorbidity
Pneumonia
Costs and Cost Analysis
Chronic Obstructive Pulmonary Disease
Heart Failure
Asthma
Population
Propensity Score
Information Storage and Retrieval
International Classification of Diseases
Linear Models
Economics
Databases
Health

Keywords

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Community-acquired pneumonia (CAP)
  • Congestive Heart Failure (CHF)
  • Diabetes
  • Economic evaluation
  • Medical cost
  • Productivity cost

ASJC Scopus subject areas

  • Health Policy

Cite this

Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults. / Polsky, Daniel E.; Bonafede, Machaon; Suaya, Jose A.

In: BMC health services research, Vol. 12, No. 1, 379, 07.11.2012.

Research output: Contribution to journalArticle

@article{0a96047bd35c4afcbc75e1b2042aa0c4,
title = "Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults",
abstract = "Abstract. Background: Adults with certain comorbid conditions have a higher risk of pneumonia than the overall population. If treatment of pneumonia is more costly in certain predictable situations, this would affect the value proposition of populations for pneumonia prevention. We estimate the economic impact of community-acquired pneumonia (CAP) for adults with asthma, diabetes, chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) in a large U.S. commercially-insured working age population. Methods. Data sources consisted of 2003 through 2007 Thomson Reuters MarketScan Commercial Claims and Encounters and Thomson Reuters Health Productivity and Management (HPM) databases. Pneumonia episodes and selected comorbidities were identified by ICD-9-CM diagnosis codes. By propensity score matching, controls were identified for pneumonia patients. Excess direct medical costs and excess productivity cost were estimated by generalized linear models (GLM). Results: We identified 402,831 patients with CAP between 2003 through 2007, with 25,560, 32,677, 16,343, and 5,062 episodes occurring in patients with asthma, diabetes, COPD and CHF, respectively. Mean excess costs (and standard error, SE) of CAP were $14,429 (SE=44) overall. Mean excess costs by comorbidity subgroup were lowest for asthma ($13,307 (SE=123)), followed by diabetes ($21,395 (SE=171)) and COPD ($23,493 (SE=197)); mean excess costs were highest for patients with CHF ($34,436 (SE=549)). On average, indirect costs comprised 21{\%} of total excess costs, ranging from 8{\%} for CHF patients to 27{\%} for COPD patients. Conclusions: Compared to patients without asthma, diabetes, COPD, or CHF, the excess cost of CAP is nearly twice as high for patients with diabetes and COPD and nearly three times as high for patients with CHF. Indirect costs made up a significant but varying portion of excess CAP costs. Returns on prevention of pneumonia would therefore be higher in adults with these comorbidities.",
keywords = "Asthma, Chronic Obstructive Pulmonary Disease (COPD), Community-acquired pneumonia (CAP), Congestive Heart Failure (CHF), Diabetes, Economic evaluation, Medical cost, Productivity cost",
author = "Polsky, {Daniel E.} and Machaon Bonafede and Suaya, {Jose A.}",
year = "2012",
month = "11",
day = "7",
doi = "10.1186/1472-6963-12-379",
language = "English (US)",
volume = "12",
journal = "BMC Health Services Research",
issn = "1472-6963",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults

AU - Polsky, Daniel E.

AU - Bonafede, Machaon

AU - Suaya, Jose A.

PY - 2012/11/7

Y1 - 2012/11/7

N2 - Abstract. Background: Adults with certain comorbid conditions have a higher risk of pneumonia than the overall population. If treatment of pneumonia is more costly in certain predictable situations, this would affect the value proposition of populations for pneumonia prevention. We estimate the economic impact of community-acquired pneumonia (CAP) for adults with asthma, diabetes, chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) in a large U.S. commercially-insured working age population. Methods. Data sources consisted of 2003 through 2007 Thomson Reuters MarketScan Commercial Claims and Encounters and Thomson Reuters Health Productivity and Management (HPM) databases. Pneumonia episodes and selected comorbidities were identified by ICD-9-CM diagnosis codes. By propensity score matching, controls were identified for pneumonia patients. Excess direct medical costs and excess productivity cost were estimated by generalized linear models (GLM). Results: We identified 402,831 patients with CAP between 2003 through 2007, with 25,560, 32,677, 16,343, and 5,062 episodes occurring in patients with asthma, diabetes, COPD and CHF, respectively. Mean excess costs (and standard error, SE) of CAP were $14,429 (SE=44) overall. Mean excess costs by comorbidity subgroup were lowest for asthma ($13,307 (SE=123)), followed by diabetes ($21,395 (SE=171)) and COPD ($23,493 (SE=197)); mean excess costs were highest for patients with CHF ($34,436 (SE=549)). On average, indirect costs comprised 21% of total excess costs, ranging from 8% for CHF patients to 27% for COPD patients. Conclusions: Compared to patients without asthma, diabetes, COPD, or CHF, the excess cost of CAP is nearly twice as high for patients with diabetes and COPD and nearly three times as high for patients with CHF. Indirect costs made up a significant but varying portion of excess CAP costs. Returns on prevention of pneumonia would therefore be higher in adults with these comorbidities.

AB - Abstract. Background: Adults with certain comorbid conditions have a higher risk of pneumonia than the overall population. If treatment of pneumonia is more costly in certain predictable situations, this would affect the value proposition of populations for pneumonia prevention. We estimate the economic impact of community-acquired pneumonia (CAP) for adults with asthma, diabetes, chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) in a large U.S. commercially-insured working age population. Methods. Data sources consisted of 2003 through 2007 Thomson Reuters MarketScan Commercial Claims and Encounters and Thomson Reuters Health Productivity and Management (HPM) databases. Pneumonia episodes and selected comorbidities were identified by ICD-9-CM diagnosis codes. By propensity score matching, controls were identified for pneumonia patients. Excess direct medical costs and excess productivity cost were estimated by generalized linear models (GLM). Results: We identified 402,831 patients with CAP between 2003 through 2007, with 25,560, 32,677, 16,343, and 5,062 episodes occurring in patients with asthma, diabetes, COPD and CHF, respectively. Mean excess costs (and standard error, SE) of CAP were $14,429 (SE=44) overall. Mean excess costs by comorbidity subgroup were lowest for asthma ($13,307 (SE=123)), followed by diabetes ($21,395 (SE=171)) and COPD ($23,493 (SE=197)); mean excess costs were highest for patients with CHF ($34,436 (SE=549)). On average, indirect costs comprised 21% of total excess costs, ranging from 8% for CHF patients to 27% for COPD patients. Conclusions: Compared to patients without asthma, diabetes, COPD, or CHF, the excess cost of CAP is nearly twice as high for patients with diabetes and COPD and nearly three times as high for patients with CHF. Indirect costs made up a significant but varying portion of excess CAP costs. Returns on prevention of pneumonia would therefore be higher in adults with these comorbidities.

KW - Asthma

KW - Chronic Obstructive Pulmonary Disease (COPD)

KW - Community-acquired pneumonia (CAP)

KW - Congestive Heart Failure (CHF)

KW - Diabetes

KW - Economic evaluation

KW - Medical cost

KW - Productivity cost

UR - http://www.scopus.com/inward/record.url?scp=84868246878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868246878&partnerID=8YFLogxK

U2 - 10.1186/1472-6963-12-379

DO - 10.1186/1472-6963-12-379

M3 - Article

C2 - 23113880

AN - SCOPUS:84868246878

VL - 12

JO - BMC Health Services Research

JF - BMC Health Services Research

SN - 1472-6963

IS - 1

M1 - 379

ER -